CN Patent

CN110114070A — 使用依维莫司(everolimus)、达托里昔布(dactolisib)或二者增强免疫反应的方法

Assigned to Novartis AG · Expires 2019-08-09 · 7y expired

What this patent protects

本发明涉及增强个体中的免疫反应的方法。

USPTO Abstract

本发明涉及增强个体中的免疫反应的方法。

Drugs covered by this patent

isavuconazonium-sulfate (ISAVUCONAZONIUM SULFATE)

Patent Metadata

Patent number: CN110114070A
Jurisdiction: CN
Classification: —
Expires: 2019-08-09
Drug substance claim: No
Drug product claim: No
Assignee: Novartis AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.